SELPLG and neoplasm: Blockade of PSGL-1 offers the potential to provide clinical benefit to patients with cancer in monotherapy due to reprogramming the abundant macrophage infiltrate residing in the tumor bed and thus overcoming the local immunosuppressive milieu.